![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TAF1L |
Gene summary for TAF1L |
![]() |
Gene information | Species | Human | Gene symbol | TAF1L | Gene ID | 138474 |
Gene name | TATA-box binding protein associated factor 1 like | |
Gene Alias | TAF(II)210 | |
Cytomap | 9p21.1 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q8IZX4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
138474 | TAF1L | HCC1 | Human | Liver | HCC | 5.09e-08 | 8.39e-01 | 0.5336 |
138474 | TAF1L | HCC2 | Human | Liver | HCC | 1.60e-10 | 7.88e-01 | 0.5341 |
138474 | TAF1L | HCC5 | Human | Liver | HCC | 2.42e-07 | 4.26e-01 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001657021 | Liver | HCC | histone modification | 283/7958 | 463/18723 | 2.68e-16 | 2.33e-14 | 283 |
GO:00182052 | Liver | HCC | peptidyl-lysine modification | 230/7958 | 376/18723 | 1.51e-13 | 8.32e-12 | 230 |
GO:00064732 | Liver | HCC | protein acetylation | 135/7958 | 201/18723 | 1.20e-12 | 5.92e-11 | 135 |
GO:00435432 | Liver | HCC | protein acylation | 157/7958 | 243/18723 | 2.40e-12 | 1.12e-10 | 157 |
GO:00183942 | Liver | HCC | peptidyl-lysine acetylation | 116/7958 | 169/18723 | 5.11e-12 | 2.23e-10 | 116 |
GO:00064752 | Liver | HCC | internal protein amino acid acetylation | 107/7958 | 160/18723 | 3.77e-10 | 1.23e-08 | 107 |
GO:00183932 | Liver | HCC | internal peptidyl-lysine acetylation | 105/7958 | 158/18723 | 9.48e-10 | 2.90e-08 | 105 |
GO:00165732 | Liver | HCC | histone acetylation | 101/7958 | 152/18723 | 1.99e-09 | 5.63e-08 | 101 |
GO:00063671 | Liver | HCC | transcription initiation from RNA polymerase II promoter | 52/7958 | 77/18723 | 7.87e-06 | 9.27e-05 | 52 |
GO:0048285 | Liver | HCC | organelle fission | 254/7958 | 488/18723 | 1.07e-05 | 1.23e-04 | 254 |
GO:0006352 | Liver | HCC | DNA-templated transcription, initiation | 78/7958 | 130/18723 | 4.19e-05 | 4.11e-04 | 78 |
GO:0000280 | Liver | HCC | nuclear division | 220/7958 | 439/18723 | 6.90e-04 | 4.25e-03 | 220 |
GO:00708971 | Liver | HCC | transcription preinitiation complex assembly | 25/7958 | 36/18723 | 9.87e-04 | 5.71e-03 | 25 |
GO:00511231 | Liver | HCC | RNA polymerase II preinitiation complex assembly | 17/7958 | 24/18723 | 4.72e-03 | 2.02e-02 | 17 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TAF1L | SNV | Missense_Mutation | c.1204G>A | p.Glu402Lys | p.E402K | Q8IZX4 | protein_coding | tolerated(0.23) | benign(0) | TCGA-05-4396-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
TAF1L | SNV | Missense_Mutation | c.889G>T | p.Val297Leu | p.V297L | Q8IZX4 | protein_coding | tolerated(0.3) | benign(0) | TCGA-05-4410-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
TAF1L | SNV | Missense_Mutation | c.4655A>G | p.Asn1552Ser | p.N1552S | Q8IZX4 | protein_coding | tolerated(0.08) | possibly_damaging(0.894) | TCGA-35-4122-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
TAF1L | SNV | Missense_Mutation | rs761229672 | c.1300N>G | p.Ile434Val | p.I434V | Q8IZX4 | protein_coding | tolerated(0.4) | benign(0.241) | TCGA-38-4631-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
TAF1L | SNV | Missense_Mutation | c.1792G>T | p.Gly598Cys | p.G598C | Q8IZX4 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-44-2656-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
TAF1L | SNV | Missense_Mutation | c.1791G>T | p.Gln597His | p.Q597H | Q8IZX4 | protein_coding | tolerated(0.14) | benign(0.18) | TCGA-44-2656-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
TAF1L | SNV | Missense_Mutation | c.4279N>A | p.Pro1427Thr | p.P1427T | Q8IZX4 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-44-2657-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TAF1L | SNV | Missense_Mutation | rs866705432 | c.2839N>T | p.His947Tyr | p.H947Y | Q8IZX4 | protein_coding | deleterious(0.01) | benign(0.028) | TCGA-44-2659-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | alimta | PD |
TAF1L | SNV | Missense_Mutation | rs774366817 | c.3044N>A | p.Arg1015His | p.R1015H | Q8IZX4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-44-2668-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
TAF1L | SNV | Missense_Mutation | c.52N>T | p.Ala18Ser | p.A18S | Q8IZX4 | protein_coding | deleterious_low_confidence(0.02) | benign(0.398) | TCGA-44-5643-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | carboplatin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |